Spots Global Cancer Trial Database for idasanutlin
Every month we try and update this database with for idasanutlin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies) | NCT02828930 | Solid Tumors | Idasanutlin Placebo [13C]-radiolabe... [14C]-radiolabe... | 18 Years - | Hoffmann-La Roche | |
| A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) | NCT02545283 | Leukemia, Myelo... | Cytarabine Idasanutlin Placebo | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors | NCT04029688 | Acute Myeloid L... Acute Lymphobla... Neuroblastoma Solid Tumors | Idasanutlin Venetoclax Cyclophosphamid... Topotecan Fludarabine Cytarabine Intrathecal Che... | 0 Years - 30 Years | Hoffmann-La Roche | |
| A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) | NCT03555149 | Colorectal Canc... | Regorafenib Atezolizumab Imprime PGG Bevacizumab Isatuximab Selicrelumab Idasanutlin AB928 LOAd703 | 18 Years - | Hoffmann-La Roche | |
| A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy | NCT02670044 | Leukemia, Myelo... | Cobimetinib Idasanutlin Venetoclax | 18 Years - | Hoffmann-La Roche | |
| A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy | NCT02670044 | Leukemia, Myelo... | Cobimetinib Idasanutlin Venetoclax | 18 Years - | Hoffmann-La Roche | |
| Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | NCT02633059 | Loss of Chromos... Recurrent Plasm... | Dexamethasone Idasanutlin Ixazomib Citrat... Laboratory Biom... Pharmacological... | 18 Years - | Mayo Clinic | |
| A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) | NCT03555149 | Colorectal Canc... | Regorafenib Atezolizumab Imprime PGG Bevacizumab Isatuximab Selicrelumab Idasanutlin AB928 LOAd703 | 18 Years - | Hoffmann-La Roche | |
| A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors | NCT03362723 | Solid Tumors | Idasanutlin | 18 Years - | Hoffmann-La Roche | |
| Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | NCT04589845 | Solid Tumors | Entrectinib Entrectinib Alectinib Atezolizumab Ipatasertib Trastuzumab emt... Idasanutlin Inavolisib Belvarafenib Pralsetinib GDC-6036 Camonsertib | - | Hoffmann-La Roche | |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera | NCT03287245 | Polycythemia Ve... | Idasanutlin | 18 Years - | Hoffmann-La Roche | |
| Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | NCT02633059 | Loss of Chromos... Recurrent Plasm... | Dexamethasone Idasanutlin Ixazomib Citrat... Laboratory Biom... Pharmacological... | 18 Years - | Mayo Clinic | |
| A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL) | NCT03135262 | Follicular Lymp... Lymphoma, Large... | Idasanutlin Obinutuzumab Venetoclax Rituximab | 18 Years - | Hoffmann-La Roche | |
| NCT Neuro Master Match - N²M² (NOA-20) | NCT03158389 | Glioblastoma, A... | APG101 Alectinib Idasanutlin Atezolizumab Vismodegib Temsirolimus Palbociclib | 18 Years - | University Hospital Heidelberg | |
| Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | NCT04589845 | Solid Tumors | Entrectinib Entrectinib Alectinib Atezolizumab Ipatasertib Trastuzumab emt... Idasanutlin Inavolisib Belvarafenib Pralsetinib GDC-6036 Camonsertib | - | Hoffmann-La Roche | |
| A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) | NCT02545283 | Leukemia, Myelo... | Cytarabine Idasanutlin Placebo | 18 Years - | Hoffmann-La Roche |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
